Journal profile · Medicine-General Medicine
Chronic Diseases and Translational Medicine
ISSN 2095-882X · eISSN 2589-0514 · KeAi Communications Co., Ltd. · China
Chronic Diseases and Translational Medicine: CAS Zone 3 · Medicine (2026 Xinrui edition); fully open access; APC about USD 2,650; median 96 days to acceptance (31 articles, last 24 months); acceptance rate 20% (journal website); 42 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Chronic Diseases and Translational Medicine is published by KeAi Communications Co., Ltd. and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are Diverse Scientific and Economic Studies, Diabetes, Cardiovascular Risks, and Lipoproteins and Human auditory perception and evaluation, together about 25.1% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Your research will be free to access, making it available to read, download and share with ease. Publish open access at no cost to you - fees are waived for a limited period. Your work will be discoverable and widely distributed with indexing by PubMed Central, Scopus, Directory of Open Access Journals and Embase. Quality and impactful research governed by an international and distinguished editorial board. Save time formatting your manuscript with Free Formatting submission. An official journal of the Chinese Medical Association.
From the journal's Aims & Scope
Research area (LetPub): Medicine-General Medicine
Editor-in-chief Jun WangPublisher website
Editorial board by country: 18 in mainland China (about 62%); most named Mainland China 18, United States 6, Germany 2, United Kingdom 1, Japan 1 (29 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance10.2%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine7.9%
- Human auditory perception and evaluationEngineering7%
- Educational Robotics and EngineeringComputer Science6.4%
- Chronic Obstructive Pulmonary Disease (COPD) ResearchMedicine5.1%
- Chronic Disease Management StrategiesMedicine4.4%
- Lipoproteins and Cardiovascular HealthMedicine4.1%
- Cancer Immunotherapy and BiomarkersMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPubMedEmbaseCASPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 4.8LetPub ·
- CiteScore (publisher)
- 4.8Publisher website ·
- CiteScore (publisher) 2025
- 4.8Publisher website ·
- SJR 2026-06
- 0.68LetPub ·
- SNIP 2026-06
- 0.74LetPub ·
- h-index
- 38OpenAlex ·
- i10-index
- 151OpenAlex ·
- 2-year mean citedness
- 1.62OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year (publisher) 2025
- 26Publisher website ·
- Downloads per year (publisher) 2025
- 108,894Publisher website ·
Articles by year OpenAlex count · 504 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 37 | 37 | 3 |
| 2025 | 42 | 42 | 27 |
| 2024 | 43 | 43 | 168 |
| 2023 | 57 | 57 | 322 |
| 2022 | 48 | 48 | 279 |
| 2021 | 35 | 35 | 421 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
96 daysMedian, submission to acceptance · P25–P75 71 days – 138 days
- Acceptance to online
- median 14 days (33 articles)
- Submission to online
- median 112 days
- Sample
- 31 articles with submission and acceptance dates (38 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 35 weeksLetPub ·
- Acceptance rate (publisher)
- 20%Publisher website ·
- Acceptance rate (publisher) 2025
- 20%Publisher website ·
- Submission to first decision
- 14 daysPublisher website ·
- Submission to first decision 2025
- 14 daysPublisher website ·
- Submission to acceptance 2025
- 69 daysPublisher website ·
- Acceptance to publication 2025
- 15 daysPublisher website ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,298 / GBP 1,949 / USD 2,650 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 0 | — | — | |
| LetPub | USD 2,650 / GBP 1,949 / EUR 2,298 | Yes | — | |
| Publisher website | USD 2,650 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Reference style
- Chicago
- First submission
- Free format: the journal's layout is not required
- Graphical abstract
- Optional
Article types accepted11, with length limits
- brief reportn either basic or clinical science. (7) Brief Report Word limit: 2000 words excluding references, tables and figures. Abstract: Not reqmain text ≤ 2,000 words
- commentaryng, both published and unpublished. (9) Commentary Word limit: 1500 words maximum excluding references. Abstract: not required. Refermain text ≤ 1,500 words
- editorialUSCRIPT CATEGORIES AND REQUIREMENTS (1) Editorial Commentary Word Limit: 1500 words maximum. Abstract: not required. Description: Proposals formain text ≤ 1,500 words
- editorial commentary(1) Editorial Commentary Word Limit: 1500 words maximum. Abstract: not required.Length not stated
- original articleist provided as an additional file. (6) Original Article Word limit: 5000 words maximum including abstract but excluding references, tablesmain text ≤ 5,000 words
- perspectivest line of the manuscript abstract. (4) Perspective Word limit: 3000 words maximum. Figures and tables: Up to 4 figures and tables inmain text ≤ 3,000 words
- protocolprocess prior to acceptance. (5) Study Protocol Word limit: 5000 words maximum including abstract but excluding references, tablesmain text ≤ 5,000 words
- reviewed paper for initial consideration. (2) Review Word limit: 10000 words maximum including abstract but excluding references, tablesmain text ≤ 10,000 words
- short communicationions will undergo full peer review. (8) Short Communication Word limit: 2000 words maximum excluding references, tables and figures. Referencemain text ≤ 2,000 words
- study protocol(5) Study Protocol Word limit: 5000 words maximum including abstract but excluding references, tables and figures.Length not stated
- systematic reviewt peer-reviewed evidence available. (3) Systematic Review Word limit: 4500 words maximum including abstract but excluding references, tablesmain text ≤ 4,500 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- AI use
AI guidelines for submissions and reviews Model summary
From 1st January 2025, all submissions and reviews must adhere to Generative artificial intelligence (AI) guidelines. Note: CDTM adopts Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics – Artificial Intelligence
Source ↗Publisher website ·- Authorship Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria:i. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work;ii. Drafting the work or revising it critically for important…
Source ↗Publisher website ·- Conflicts of interest Disclosure
Articles are required to include a disclosure statement. The statement should disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. Authors without conflicts of interest should include a statement of no such intere…
Source ↗Publisher website ·- Publication ethics Publication Ethics
Follows COPE core practices Model summary
This journal follows the core practices of the Committee on Publication Ethics (COPE) and handles cases of research and publication misconduct accordingly (https://publicationethics.org/core-practices). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wi…
Source ↗Publisher website ·- License & copyright Reproduction of Copyright Material
If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is the author’s responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ at http://exchanges.wiley.com/authors/faqs---copyright-terms--conditions_301.html
Source ↗Publisher website ·- Peer review Peer Review
Double-blind peer review Model summary
Chronic Diseases and Translational Medicine uses double-blind peer review, which means the identities of the authors are concealed from the reviewers, and vice versa. Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the m…
Source ↗Publisher website ·- Plagiarism
Uses iThenticate CrossCheck Model summary
Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts.
Source ↗Publisher website ·- Preprints Preprint
J. Chae, S. Shin, S. Lee, and J. K. Kim, “From Homogeneity to Heterogeneity: Refining Stochastic Simulations of Gene Regulation,” preprint, bioRxiv, September 24, 2024, https://doi.org/10.1101/2024.09.24.614828.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectivel…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- KeAi Communications Co., Ltd.
- Country or region
- China
- Language
- English
- ISSN
- 2095-882X
- Electronic ISSN
- 2589-0514
- Society / sponsor
- Chinese Medical Association
- Latest issue on the website
- Volume 12, Issue 3 (September 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Chronic Diseases and Translational Medicine
What CAS zone is Chronic Diseases and Translational Medicine in?
In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Chronic Diseases and Translational Medicine?
Based on the dates recorded on 31 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 96 days (interquartile range 71–138 days); authors report an average review time of about 35 weeks; the journal's website gives an acceptance rate of 20% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Chronic Diseases and Translational Medicine?
According to the journal's author guidelines: Reference style: Chicago; First submission: Free format: the journal's layout is not required; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Chronic Diseases and Translational Medicine based?
Of the 29 board members whose country the journal's board page names, 18 (about 62%) are in mainland China; the countries named most often are Mainland China (18), United States (6) and Germany (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Chronic Diseases and Translational Medicine?
According to LetPub and DOAJ records, Chronic Diseases and Translational Medicine is indexed in Scopus and DOAJ. The journal's website also lists PMC, PubMed, Embase and CAS; that list has not been checked against each database.
Is Chronic Diseases and Translational Medicine open access, and what is the APC?
Chronic Diseases and Translational Medicine is a fully open-access journal. APC about USD 2,650.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .